GIVLAARI (givosiran)

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.

Therapeutic Areas